Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study

BACKGROUND: Trabectedin has shown efficacy against soft tissue sarcomas (STS) and has manageable toxicity. Trabectedin is administered through central venous access devices (VAD), such as subcutaneous ports with tunneled catheters, Hickman catheters and PICC lines. Venous access related adverse even...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Sarcoma Res
Autori principali: Verboom, Michiel C., Ouwerkerk, Jan, Steeghs, Neeltje, Lutjeboer, Jacob, Martijn Kerst, J., van der Graaf, Winette T. A., Reyners, Anna K. L., Sleijfer, Stefan, Gelderblom, Hans
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5282803/
https://ncbi.nlm.nih.gov/pubmed/28163887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-017-0066-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi